High-risk prostate cancer: treat the prostate
Published:November 03, 2011DOI:https://doi.org/10.1016/S0140-6736(11)61254-3
Hundreds of thousands of men are diagnosed with clinically localised prostate cancer every year, and each faces a complex treatment decision with little high-quality evidence to help choose among treatments. Successfully completed, randomised trials of active treatments for localised prostate cancer are, unfortunately, scarce; a large systematic review commissioned by the US Agency for Healthcare Research and Quality noted that insufficient evidence exists to make conclusions about the relative benefits and harms of treatments.
The US Institute of Medicine has identified prostate cancer as among the USA’s top 25 priorities for future comparative effectiveness research.
This article is available free of charge.
Simply log in to access the full article, or register for free if you do not yet have a username and password.
Already registered?
Not yet registered?
References
- 1.
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Ann Intern Med. 2008; 148: 435-448
- 2.
Initial national priorities for comparative effectiveness research.National Academies Press, Washington, DC2009: 1-253
- 3.
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Lancet. 2011; (published online Nov 3.)https://doi.org/10.1016/S0140-6736(11)61095-7
- 4.
The quality-of-life impact of prostate cancer treatments.
Curr Urol Rep. 2010; 11: 139-146
- 5.
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Urology. 2000; 56: 899-905
- 6.
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Lancet. 2008; 373: 301-308
- 7.
Guideline for the management of clinically localized prostate cancer: 2007 update.
J Urol. 2007; 177: 2106-2131
- 8.
NCCN clinical practice guidelines in oncology: prostate cancer.
J Natl Compr Canc Netw. 2010; 8: 162-200
- 9.
Survival following primary androgen deprivation therapy among men with localized prostate cancer.
JAMA. 2008; 300: 173-181
- 10.
Impact of age at diagnosis on prostate cancer treatment and survival.
J Clin Oncol. 2011; 29: 235-241
- 11.
Outcomes of localized prostate cancer following conservative management.
JAMA. 2009; 302: 1202-1209
- 12.
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.
J Clin Oncol. 2010; 28: 1508-1513
- 13.
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cancer. 2010; 116: 5226-5234
Article info
Publication history
Published: November 03, 2011
Identification
Copyright
© 2011 Elsevier Ltd. All rights reserved.
ScienceDirect
Linked Articles
Related Specialty Collections
This article can be found in the following collections: